Investors & Media

Press releases

Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair

Visit our newsroom

Upcoming & recent events

Goldman Sachs 47th Annual Global Healthcare Conference

View event details

2026 Annual Meeting of Shareholders

Listen to webcast

View event details

View investor events

Quarterly materials

Show all

Q1 2026

Market Cap:

May 18, 2026 7:08 AM EDT

Minimum 15 minutes delayed. Source: LSEG

Interactive analyst center

Interactive and downloadable financial data for investors and analysts.

View analyst center

Corporate responsibility

We're dedicated to responsible business practices, integrating the highest standards of integrity into every facet of our operations.

Learn about our approach to corporate responsibility

Contact us

Investors

914.847.7741

invest@regeneron.com

Media

media@regeneron.com

Sign up for email alerts

Regeneron corporate and R&D headquarters